Why the study?
Does treatment with cyclosporin A or verapamil prevent heart disease development in K(v)4.2N transgenic mice?
Population
K(v)4.2N transgenic mice (evaluated at 3-4 weeks and 13-15 weeks of age)
Comparison
Treatment with either cyclosporin A or verapamil vs Control mice and untreated K(v)4.2N mice
Design
Preclinical
Follow-up
Up to 13-15 weeks of age
Authors
Loading...
Attenuates pathology in this mouse model; leaves open translation to human heart failure.
Does treatment with cyclosporin A or verapamil prevent heart disease development in K(v)4.2N transgenic mice?
Inhibition of calcineurin or L-type Ca2+ channels prevents cardiac hypertrophy, fibrosis, and contractile dysfunction in a transgenic mouse model of heart failure induced by K(v)4.2N expression.
Sah et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: